Survival rates and HRs for mortality in recipients of less-intensive vs intensive induction therapies within the retrospective cohort
| . | 2-y OS, % . | Unadjusted . | Adjusted for HCT as time-dependent covariate . | |||
|---|---|---|---|---|---|---|
| AML-CM . | Less intensive . | Intensive . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| 4-6 | 29 | 56 | 1.82 (1.25-2.63) | .002 | 1.82 (1.25-2.63) | .002 |
| 7-9 | 17 | 36 | 1.79 (1.32-2.44) | .0002 | 1.67 (1.22-2.27) | .002 |
| ≥10 | 8 | 22 | 1.43 (1.08-1.89) | .01 | 1.32 (0.99-1.72) | .06 |
| Missing | 24 | 49 | 2.04 (1.37-3.13) | .0006 | — | — |
| . | 2-y OS, % . | Unadjusted . | Adjusted for HCT as time-dependent covariate . | |||
|---|---|---|---|---|---|---|
| AML-CM . | Less intensive . | Intensive . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| 4-6 | 29 | 56 | 1.82 (1.25-2.63) | .002 | 1.82 (1.25-2.63) | .002 |
| 7-9 | 17 | 36 | 1.79 (1.32-2.44) | .0002 | 1.67 (1.22-2.27) | .002 |
| ≥10 | 8 | 22 | 1.43 (1.08-1.89) | .01 | 1.32 (0.99-1.72) | .06 |
| Missing | 24 | 49 | 2.04 (1.37-3.13) | .0006 | — | — |
Comparisons stratified according to AML-CM score. No comparisons were performed for patients with AML-CM score ≤3 because 99% received intensive therapies. HR comparisons are both unadjusted and adjusted for undergoing allogeneic HCT as time-dependent covariate. Higher HR indicates increased mortality with less-intensive therapies.
OS, overall survival.